Leonard Bell, M.D.

Dr. Bell was the principal founder of Alexion in 1992 and served as the Chief Executive Officer from the Company’s inception until he retired as CEO on March 31, 2015. Under his leadership Alexion grew to become a global biopharmaceutical company with employees serving patients with severe and life-threatening disorders in 50 countries through fully integrated research, discovery, development, manufacturing, and commercial capabilities.

Prior to founding Alexion, Dr. Bell was an attending physician at Yale-New Haven Hospital and Assistant Professor of Medicine and Pathology at the Yale University School of Medicine, where he also received his M.D. degree. Dr. Bell was a recipient of the numerous awards and honors as an academic scientist prior to founding Alexion.

Dr. Bell received his A.B. from Brown University and M.D. from Yale University School of Medicine. Dr. Bell is currently an Adjunct Assistant Professor of Medicine and Pathology at the Yale University School of Medicine.

Steve Squinto, Ph.D.

Stephen Squinto, Ph.D., is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience.  Dr. Squinto was a co-founder of Alexion Pharmaceuticals, Inc. and most recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion's Global Head of Research and Development.  From 1988 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc.  
Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools.  He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work.  
Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.

Carrolee Barlow, M.D., Ph.D.

Dr. Carrolee Barlow, M.D., Ph.D., B.A., has been Chief Executive Officer of The Parkinson's Institute since March 5, 2013. Dr. Barlow most recently served as the Chief Scientific and Medical Officer of BrainCells, Inc. a company she joined in 2004.  She also served as the Director of Molecular Neuroscience and the Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories, a company she joined in 2002.  Prior to joining Merck, she held a faculty position in the Laboratory of Genetics at the Salk Institute for Biological Studies in La Jolla, California, where she maintained an adjunct appointment. She served as a Scientific Advisor of Bionomics Ltd. until September 22, 2016. At the Salk Institute, her research laboratory focused on developing animal models of human neurological disease.

Dr. Barlow received her M.D. from the University of Utah followed by a residency at The New York Hospital, Cornell Medical Center in Internal Medicine. She obtained a Ph.D. in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. She completed medical subspecialty training in the field of endocrinology at the NIH and a post-doctoral fellowship in neurogenetics at the National Human Genome Research Institute.

Roy Alcalay, M.D.

Roy Alcalay, M.D., is the Florence Irving Assistant Professor of Neurology at Columbia University Medical Center. He obtained his medical degree from Tel Aviv University, Israel, his neurology training from the Harvard University residency program at Massachusetts General Hospital and Brigham and Women’s Hospital and his movement disorders training at Columbia University.

He is a graduate of the Patient Oriented Research and earned Master’s in biostatistics from Columbia University. His research focuses on biomarkers and genetics in Parkinson’s disease and cognitive functioning. He is a Brookdale Leadership in Aging fellow, and his research is supported by the NIH, the Parkinson’s Disease Foundation, the Michael J Fox Foundation and the Smart Foundation.

Julian Adams, Ph.D.

Dr. Adams has more than 30 years of experience in drug discovery and development with a strong focus on cancer research. Dr Adams, recently joined Gamida Cell as Chairman, and also serves Clal Biotechnology Industries as its Chief Scientific Officer and President. He was previously president of research and development at Infinity Pharmaceuticals. Prior to joining Infinity in 2003, Dr. Adams was the senior vice president of drug discovery and development at Millennium Pharmaceuticals, where he headed multiple global drug discovery and development programs, including the successful Velcade® (bortezomib) program.

Dr. Adams also held senior positions in research and development at LeukoSite (acquired by Millennium) and at ProScript, as well as in medicinal chemistry at Boehringer Ingelheim, where he is credited with discovering Viramune® (nevirapine) for HIV. Dr. Adams has won many awards, holds 40+ patents and has authored more than 100 papers and book chapters in peer-reviewed journals. He earned a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology. He also received a Doctor of Science, honoris causa, from McGill University in 2012.

Gregory Grabowski, M.D.

Dr. Grabowski is Professor Emeritus of Pediatrics and Genetics at the Cincinnati Children’s Hospital Research Foundation, and Chief Scientific Officer of Kiniksa Pharmaceuticals. He most recently served as Chief Scientific Officer of Synageva BioPharma, before its acquisition by Alexion in June 2015. Prior to that, Dr. Grabowski spent over 20 years at Cincinnati Children’s Hospital Medical Center, where he was the A. Graeme Mitchell Chair of Human Genetics and Director of Human Genetics at the Children’s Hospital Research Foundation. He was also a Professor in the Departments of Molecular Genetics and Biochemistry, and Pediatrics, at the University of Cincinnati College of Medicine. Previously, Dr. Grabowski spent 13.5 years at the Mount Sinai School of Medicine, where he developed the world’s largest clinic for patients afflicted with Gaucher disease and other lysosomal diseases. He established basic research and diagnostic laboratories for genetic diseases as well as the first treatment center for enzyme therapy in Gaucher disease.
 
Dr. Grabowski received his M.D. from the University of Minnesota where he also completed his residency in Pediatrics and fellowship training in Human Genetics. During his research career, he has published over 330 scholarly works on the basic and clinical sciences of lysosomal storage and genetic diseases, while maintaining active clinical and treatment programs for genetic diseases.

Geoffrey Levin

Geoffrey Levin is a Partner in Sidley’s New York office. He concentrates his practice on complex business transactions and governance matters for private equity sponsors and their portfolio companies. Geoff has more than 20 years of experience representing clients across a number of industries in a variety of transactional matters, including domestic and cross-border M&A, leveraged buyouts, going private transactions, proxy contests, spin-offs,  joint ventures, recapitalizations, venture capital financing, growth equity investments, PIPEs, debt financings, restructurings and workouts. Geoff's representations have covered a broad range of industries including life sciences, financial services, communications, energy, retail, automotive and heavy industrial. Geoff regularly comments on developments in the healthcare industry and speaks at investment conferences. He is the author of “New M&A Concerns and Strategies” that recently appeared in Aspatore Books Inside the Mind series. He is listed by IFLR 1000 as a leading M&A lawyer and has been recognized by Institutional Investor News as one of the “10 Rising Stars of Private Equity and M&A Law” and by Mergermarket as a 2009 “Dealmaker of the Year.”